Lacosamide Tablets Recall Due to Foreign Tablet Mix-Up
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Annora Pharma Private Limited is recalling 31,392 bottles of Lacosamide Tablets USP 100mg after a possible mix-up with Selexipag tablets.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 3, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Annora Pharma Private Limited initiated a voluntary recall due to the presence of a foreign tablet. A complaint indicated a possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg.
Which Products Are Affected
Lacosamide Tablets, USP, C V, 100mg, Rx only, 60-count bottle, NDC 31722-813-60. Manufactured for Camber Pharmaceuticals, Inc. by Annora Pharma Pvt., Ltd. Affected lots are A253999 and A254000, expiring 09/30/2027. A total of 31,392 60-count bottles are involved. Distribution was nationwide in the USA.
What You Should Do
Consumers with questions should contact the recalling firm or their pharmacist. The recall was initiated via E-Mail on June 4, 2026.
Why This Matters
This Class II recall addresses a potential medication mix-up that could result in temporary or reversible adverse health consequences.
Source
FDA recall D-0626-2026
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (913 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 3, 2026.
Frequently Asked Questions
Common questions about this FDA recall.